Novel approaches to therapy in CML.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Tyrosine kinase inhibitors (TKIs) are effective in managing chronic myeloid leukemia (CML), inducing remission and prolonging survival.
• However, TKIs do not eliminate leukemia stem cells (LSCs), leading to disease relapse upon treatment discontinuation.
• LSC persistence is a major obstacle to achieving cures and treatment-free remissions in CML.

Purpose of the Study:

• To review the mechanisms of LSC resistance to TKIs in CML.
• To discuss novel strategies and clinical trials targeting CML LSCs.
• To identify challenges in eradicating LSCs for CML cure.

Main Methods:

• Literature review of studies on CML pathogenesis and TKI resistance.
• Analysis of mechanisms underlying LSC maintenance (BCR-ABL kinase-independent).
• Examination of cell-intrinsic and microenvironmental factors contributing to LSC persistence.

Main Results:

• LSC persistence is driven by BCR-ABL kinase-independent mechanisms.
• Both intrinsic cellular processes and the surrounding microenvironment contribute to LSC survival.
• Emerging therapeutic approaches aim to target these LSC-specific vulnerabilities.

Conclusions:

• Targeting LSCs is crucial for achieving durable remissions and potential cures in CML.
• Overcoming LSC resistance requires a deeper understanding of both intrinsic and extrinsic factors.
• Further research and clinical trials are essential to develop effective LSC-directed therapies for CML.